Please try another search
DNA Chip Research Inc. is primarily engaged in DNA chip-related analysis and next-generation sequence related technology research business, and diagnostic business which is engaged in the sales of medical-related equipment centered on EGFR-NGS Check. The Contract Research segment is engaged in the microarray, next-generation sequencing experiment analysis to universities and research institutes, pharmaceutical and food companies. The Diagnostic segemnt utilizes genetic analysis technology to disseminate tests corresponding to social needs on personalized medicine and undiseased society. The main menu of the diagnostic business is EGFR-NGS Check. The Research and Development segment includes research on cancer diagnosis technology using next generation sequencer, as well as the development of RNA check.
Name | Age | Since | Title |
---|---|---|---|
Ryo Matoba | 56 | 2010 | President, CEO & Representative Director |
Keiji Sato | 44 | 2019 | GM of Diagnostic Business Headquarters & Director |
Tokio Katayama | 79 | 2014 | Independent Outside Director |
Kunio Yamada | 71 | 2015 | Independent Outside Director |
Shoko Kawamoto | 59 | 2021 | Independent Outside Director |
Takaaki Sato | 64 | 2019 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review